The DOI matches its Crossref record; the references it cites are not checked yet.
Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway
Open accessAbstract
Background The prognosis of pancreatic cancer is poor and new treatment strategies are urgently needed. To identify non-cancer drugs that could be re-purposed for cancer, we investigated the association between the use of selected drugs and cancer-specific mortality in a nationwide cohort of pancreatic cancer patients. Material and methods The study is based on linkage between the Cancer Registry of Norway and the Norwegian Prescription Database, comprising 2614 pancreatic cancer patients diagnosed between 2007 and 2014. We evaluated the association between use at diagnosis of a pre-defined list of non-cancer drugs, including metformin, antihypertensives, and statins, and pancreatic cancer-specific mortality, using Cox regression. Patients were defined as users of a particular drug if it was prescribed before diagnosis, and the prescription covered the date of diagnosis. Results In total, 2096 (80.2%) patients died from pancreatic cancer; median survival was 6 months. Statin users (n = 621) had lower mortality (hazard ratio (HR): 0.86; 95% confidence interval (CI) 0.76–0.97) compared to non-users (n = 1993). This association was more pronounced (P-heterogeneity 0.062) in users of hydrophilic (n = 37, HR: 0.61; 95% CI 0.42–0.90) than lipophilic (n = 587, HR: 0.87; 95% CI 0.78–0.98) statins. An indication for lower mortality (HR: 0.85; 95% CI 0.69–1.05) was observed in users of non-selective beta-blockers (n = 113) compared to non-users (n = 2501). Notably, when compared to use…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the Norwegian registry analysis by Stoer et al. did not identify a significant OS difference between lipophilic and hydrophilic statins”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Stoer et al., 2021
In the citing paper
“The study compared the effect of lipophilic statins with the effect of the hydrophilic statins, with no statistically significant difference (Stoer et al., 2021).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Stoer et al., 2021
In the citing paper
“Stoer et al., in a nationwide Norwegian study, reported a better OS in the statin-treated PDAC patients compared to the PDAC patients not treated with statins (HR 0.86, 95% CI 0.76–0.97).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Stoer et al., 2021
Citations
The citation lists are queued
They are fetched later and appear here then.
References 55 · Cited by 22
Research works printed but not linked: 2
- Kheloussi S., 2018, US Pharm, 43, 22
- Li G, 2017, Int J Epidemiol, 46, 746
Metadata
- Authors
- Støer, N. C., Bouche, G., Pantziarka, P., Sloan, E. K., Andreassen, B. K., & Botteri, E.
- Affiliations
- Cancer Registry of Norway (NO)
- Anticancer Fund (BE)
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Støer, Nathalie C.
- ORCID
- Venue
- Acta Oncologica
- Published
- 2021-08-02
- Volume
- 60
- Issue
- 9
- Pages
- 1146-1153
- ISSN
- 0284-186X (ISSN-L)
- 1651-226X
- OpenAlex
- W3192882316
- Cited by
- 22
- References
- 55
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 4 · 2022: 3
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Acta Oncologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, cancer-specific mortality, statins, non-selective beta-blockers, metformin, antihypertensive drugs, drug repurposing, cancer prognosis, hydrophilic statins, survival, prescription drug use, Norwegian Prescription Database, drug-drug interactions
- MeSH terms
- Adenocarcinoma, Humans, Metformin, Pancreatic Neoplasms, Registries, Cohort Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. https://app.cochat.ai/papers/10.1080/0284186x.2021.1953136
- The paper
- Støer, N. C., Bouche, G., Pantziarka, P., Sloan, E. K., Andreassen, B. K., & Botteri, E. (2021). Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. Acta Oncologica. https://doi.org/10.1080/0284186x.2021.1953136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.